The body's natural opioid system (endorphins) is part of a wound-healing process that suppresses local immune response. Cancers, particularly melanoma, exploit this by producing their own opioids, using a natural healing mechanism to hide from the immune system and promote their growth.
Glycyx's drug is designed not to cross the blood-brain barrier. This allows medicinal opioids to provide pain relief by acting on the brain, while the new drug antagonizes opioid receptors throughout the rest of the body, preventing negative side effects like immune suppression.
Contrary to the standard research path of testing in animals before humans, scientists first observed that cancer patients on opioids had poorer immunotherapy outcomes. They then validated this clinical observation by recreating the effect in animal models to understand the underlying biological mechanism, reversing the typical discovery pipeline.
Melanoma cells naturally produce high levels of endorphins (natural opioids) because the gene for beta-endorphin is part of a large complex that also creates melanocyte-stimulating hormone, a key growth driver for melanoma. This genetic quirk gives melanoma an inherent ability to suppress the immune system, making it a prime target for opioid-blocking therapies.